medpundit |
||
|
Sunday, April 10, 2005Federal regulators let the arthritis drug Vioxx stay on the market for more than four years despite clinical trials linking it to heart attacks and strokes. This week, they asked the makers of Advil, Aleve, Mobic, and other popular painkillers to add stern warnings about cardiovascular side effects to their labels - despite a lack of strong data showing a risk. 'The FDA has sort of swung from saying there's no problem to saying everything is a problem,' said Garrett FitzGerald, a University of Pennsylvania cardiologist and pharmacologist. Some health-care providers and patients say they are confused, not comforted, by the U.S. Food and Drug Administration's sudden regulatory conservatism. And some experts say it renews questions about whether the FDA is influenced by politics and public relations. I think this means the precautionary principle has won. posted by Sydney on 4/10/2005 08:18:00 AM 0 comments 0 Comments: |
|